TherapeuticsMD Announces Third Quarter 2026 Financial Results
TherapeuticsMD reported third-quarter 2026 net income from continuing operations of $501,000, or $0.04 per basic and diluted share. The excerpt compares this with income of $50,000, or $0.00 per share, in the prior-year period.
Why it matters — The report gives TXMD watchers an update on the company’s continuing-operations results and the year-over-year comparison.